GTx (GTXI) vs. Its Peers Financial Comparison
GTx (NASDAQ: GTXI) is one of 196 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare GTx to related businesses based on the strength of its risk, dividends, analyst recommendations, profitability, valuation, earnings and institutional ownership.
Valuation and Earnings
This table compares GTx and its peers revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|GTx Competitors||$207.14 million||-$2.51 million||0.28|
GTx’s peers have higher revenue and earnings than GTx. GTx is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares GTx and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
GTx has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Comparatively, GTx’s peers have a beta of 1.67, indicating that their average share price is 67% more volatile than the S&P 500.
This is a breakdown of recent recommendations and price targets for GTx and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Biotechnology & Medical Research” companies have a potential upside of 10.24%. Given GTx’s peers higher possible upside, analysts clearly believe GTx has less favorable growth aspects than its peers.
Institutional & Insider Ownership
9.1% of GTx shares are held by institutional investors. Comparatively, 49.5% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 41.2% of GTx shares are held by insiders. Comparatively, 14.3% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
GTx peers beat GTx on 6 of the 9 factors compared.
GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its lead product candidate, enobosarm (GTx-024), had been evaluated in over 24 completed or ongoing clinical trials, including in approximately six Phase II and two Phase III clinical trials. The Company is also engaged in the development of GTx-758 (Capesaris), an oral nonsteroidal selective estrogen receptor alpha agonist, for secondary hormonal therapy in men with metastatic and high-risk non-metastatic castration resistant prostate cancer (CRPC). Its product candidate, Enobosarm, for the treatment of women with advanced androgen receptor (AR) positive triple-negative breast cancer (TNBC), is in Phase II clinical development-stage.
Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.